Chunmei Feng, Xiaojing Liu, Linglin Zhang, Hui Tao, Xiuli Wang, Peiru Wang, Haiyan Zhang, Yan Zhao, Yamei Chen
Journal: Photodiagnosis and photodynamic therapy 2024;49():104304
PMID: 39226754
BACKGROUND
Acne vulgaris is a chronic inflammatory skin disease involving the pilosebaceous unit.
OBJECTIVE
To assess the efficacy and safety of a chlorin e6 derivative-mediated photodynamic therapy (STBF-PDT) in the treatment of mild to moderate acne patients.
METHODS
In this prospective patient single-blind randomized split-face controlled study, patients diagnosed with mild to moderate acne were treated with four sessions of STBF-PDT on one-half of the face, while the other half were treated with the same dose of red-light treatment without photosensitizer. Follow-up assessment including the skin lesion clearance rate, facial fluorescence scattering spots on VISIA Porphyrins mode, and skin physiological parameters was conducted before and after treatment as well as 2 and 4 weeks after the final treatment.
RESULTS
A total of 26 patients were recruited, of which 22 patients completed this study. STBF-PDT is significantly effective in improving lesions in patients with acne. The clearance rate of total lesions was 67.42±8.51 % in the STBF-PDT group and 41.05±11.97 % in the control group 4 weeks after the treatment (P < 0.001). The average clearance rate of inflammatory lesions was 84.41±7.13 % in the STBF-PDT group and 50.10±13.91 % in the control group, with a statistically significance (P < 0.0001). The skin sebum of the STBF-PDT side was significantly lower than that on the control side. There was no obvious adverse reaction especially no pain or reactive acne.
CONCLUSION
STBF-PDT may be a safe and effective treatment for mild to moderate acne and can significantly inhibit sebum secretion.
Copyright © 2024. Published by Elsevier B.V.
Full Text Sources:
Medical:
Full Text Sources:
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.